The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension.
During three-month therapy with small doses of guanfacine (Estulic Sandoz) that were sufficient to control blood pressure in patients with stage II essential hypertension and led to a decrease in excretion of noradrenaline and vanillylmandelic acid, the authors found a decrease in the level of blood cholesterol in patients with hyperlipidaemia. There was no adverse effect on the levels of triglycerides, beta, pre-beta and alpha lipoproteins. The authors conclude that Estulic therapy is indicated in patients who, in addition to essential hypertension, have hyperlipidaemia.
Balazovjech
I
I
First Medical Department, Comenius University Faculty of Medicine, Bratislava, Czechoslovakia.
Skultétyová
D
D
Mikulecký
M
M
Kratochvíl'ová
H
H
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000652:urine*; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood
D000959:Antihypertensive Agents; D002395:Catecholamines; D006146:Guanidines; D008055:Lipids; D008074:Lipoproteins; D010648:Phenylacetates; D014280:Triglycerides; D016316:Guanfacine; D002784:Cholesterol